busulfan has been researched along with Diffuse Mixed Small and Large Cell Lymphoma in 93 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "We retrospectively evaluated early and long-term complications of an intensified conditioning regimen consisting of busulfan and etoposide in combination with either nimustine hydrochloride (ACNU) (BVA regimen, n = 18) or melphalan (BVL regimen, n = 34) in 52 children with acute leukemia or non-Hodgkin's lymphoma." | 7.74 | Long-term follow-up of busulfan, etoposide, and nimustine hydrochloride (ACNU) or melphalan as conditioning regimens for childhood acute leukemia and lymphoma. ( Fujioka, K; Funabiki, T; Goto, H; Goto, S; Hanzawa, N; Ikuta, K; Izaki, S; Kai, S; Matsuda, M; Okuda, K; Sasaki, H; Sekiguchi, H; Sumita, H; Takahashi, H; Watanabe, Y; Yokota, S, 2007) |
| "The combination of busulfan and cyclophosphamide has seldom been employed as a conditioning regimen for patients with lymphoma." | 7.69 | Busulfan and cyclophosphamide (BU/CY2) as preparative regimen for patients with lymphoma. ( Ball, E; de Magalhaes-Silverman, M; Lister, J; Rybka, W; Wilson, J, 1997) |
| "The study initially enrolled Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) patients ages 18 to 80 years but was amended due to high early treatment-related mortality (TRM) in patients > 65 years." | 6.82 | Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes. ( Ai, W; Bence-Bruckler, I; Bierman, P; Braunschweig, I; Chen, AI; Comeau, T; Costa, LJ; Craig, M; Fay, JW; Flinn, I; Flowers, CR; Freytes, CO; Horwitz, ME; Kato, K; Laneuville, P; Le-Rademacher, J; Lill, M; Mason, J; Mineishi, S; Pasquini, MC; Pulsipher, MA; Rodriguez, TE; Rondelli, D; Shea, TC; Shore, TB; Smith, AJ; Vaughan, W; Waller, EK; Wang, Y; Xu, C; Yeager, AM; Yeh, RF, 2016) |
| " To facilitate a therapeutic dose-monitoring protocol, we transitioned from Bu6 to daily Bu dosing for patients with Hodgkin and non-Hodgkin lymphoma undergoing autologous stem cell transplantation (ASCT)." | 5.43 | Daily Weight-Based Busulfan with Cyclophosphamide and Etoposide Produces Comparable Outcomes to Four-Times-Daily Busulfan Dosing for Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. ( Andresen, S; Bolwell, BJ; Carlstrom, KD; Dean, R; Gerds, A; Hamilton, B; Hill, BT; Jagadeesh, D; Kalaycio, M; Liu, H; Majhail, NS; Pohlman, B; Rybicki, L; Sobecks, R, 2016) |
| " Routine dosing on the basis of BSA or AIBW in adults and adolescents does not require a specific accommodation for the obese." | 5.30 | The impact of obesity and disease on busulfan oral clearance in adults. ( Appelbaum, FR; Corneau, B; Gibbs, JP; Gooley, T; Murray, G; Slattery, JT; Stewart, P, 1999) |
| " Cyclosporin A and short methotrexate were used for graft-versus-host disease (GVHD) prophylaxis." | 5.08 | Combined transplantation of allogeneic bone marrow and CD34+ blood cells. ( Arseniev, L; Bähre, O; Battmer, K; Berenson, RJ; Casper, J; Diedrich, H; Jacobs, R; Kadar, JG; Kühl, J; Link, H; Poliwoda, H; Schubert, J, 1995) |
| "Sixteen patients with poor-prognosis acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and non-Hodgkin's lymphoma (NHL) underwent conditioning with busulfan (16 mg/kg) and cyclophosphamide (120 mg/kg) (BUCY-2) plus melphalan (90 or 135 mg/m2) and autologous bone marrow transplantation (AuBMT) in a phase I study." | 5.07 | Busulfan, cyclophosphamide, and melphalan conditioning for autologous bone marrow transplantation in hematologic malignancy. ( Barnett, MJ; Chan, KW; Klingemann, HG; Lansdorp, PM; Nevill, TJ; Phillips, GL; Reece, DE; Shepherd, JD; Spinelli, JJ, 1991) |
| "We retrospectively evaluated early and long-term complications of an intensified conditioning regimen consisting of busulfan and etoposide in combination with either nimustine hydrochloride (ACNU) (BVA regimen, n = 18) or melphalan (BVL regimen, n = 34) in 52 children with acute leukemia or non-Hodgkin's lymphoma." | 3.74 | Long-term follow-up of busulfan, etoposide, and nimustine hydrochloride (ACNU) or melphalan as conditioning regimens for childhood acute leukemia and lymphoma. ( Fujioka, K; Funabiki, T; Goto, H; Goto, S; Hanzawa, N; Ikuta, K; Izaki, S; Kai, S; Matsuda, M; Okuda, K; Sasaki, H; Sekiguchi, H; Sumita, H; Takahashi, H; Watanabe, Y; Yokota, S, 2007) |
| "The combination of busulfan and cyclophosphamide has seldom been employed as a conditioning regimen for patients with lymphoma." | 3.69 | Busulfan and cyclophosphamide (BU/CY2) as preparative regimen for patients with lymphoma. ( Ball, E; de Magalhaes-Silverman, M; Lister, J; Rybka, W; Wilson, J, 1997) |
| "The study initially enrolled Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) patients ages 18 to 80 years but was amended due to high early treatment-related mortality (TRM) in patients > 65 years." | 2.82 | Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes. ( Ai, W; Bence-Bruckler, I; Bierman, P; Braunschweig, I; Chen, AI; Comeau, T; Costa, LJ; Craig, M; Fay, JW; Flinn, I; Flowers, CR; Freytes, CO; Horwitz, ME; Kato, K; Laneuville, P; Le-Rademacher, J; Lill, M; Mason, J; Mineishi, S; Pasquini, MC; Pulsipher, MA; Rodriguez, TE; Rondelli, D; Shea, TC; Shore, TB; Smith, AJ; Vaughan, W; Waller, EK; Wang, Y; Xu, C; Yeager, AM; Yeh, RF, 2016) |
| "One hundred two patients (Hodgkin lymphoma n = 49, non-Hodgkin lymphoma n = 12, multiple myeloma = 41) with a median age of 44 years (range: 19-65 years) were treated." | 2.76 | Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies. ( Andersson, BS; Champlin, RE; Hosing, C; Jones, RB; Kazerooni, R; Kebriaei, P; Khouri, I; Ledesma, C; Madden, T; Nieto, Y; Popat, U; Qazilbash, M; Shpall, EJ; Thall, PF; Wang, X, 2011) |
| " In summary, the combination of treosulfan and fludarabine is a safe and efficient conditioning regimen." | 2.71 | Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. ( Casper, J; Dölken, G; Freund, M; Hammer, U; Hartung, G; Kiefer, T; Kleine, HD; Knauf, W; Knopp, A; Steiner, B; Wegener, R; Wilhelm, S; Wolff, D, 2004) |
| "Ten patients who relapsed are alive a median of 31 months (range, 6-47) after relapse." | 2.69 | High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma. ( Buckner, CD; Rhinehart, S; Schwartzberg, L; Weaver, CH; West, J; West, WH; Zhen, B, 1998) |
| " G-CSF was given at variable dosage based on neutrophil count." | 2.66 | Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation. ( Dodds, A; Fox, RM; Green, MD; Layton, JE; Lusk, J; Maher, D; Morstyn, G; Sheridan, WP; Souza, L; Wolf, M, 1989) |
| "The technique of high-dose chemotherapy and bone-marrow transplantation takes advantage of any potential dose-response effect in the treatment of cancer and the ability of infused marrow to circumvent severe myelotoxicity." | 2.38 | High-dose chemotherapy with busulphan and cyclophosphamide and bone-marrow transplantation for drug-sensitive malignancies in adults: a preliminary report. ( Boyd, AW; Brodie, GN; Green, MD; Griffiths, JD; McGrath, KM; Russell, DM; Scarlett, JD; Sheridan, WP; Thomas, RJ; Vaughan, SL, 1989) |
| " At our institution, Bu was previously administered with fixed weight-based dosing (WBD) in combination with cyclophosphamide (Cy) and etoposide (E) for patients with non-Hodgkin lymphoma (NHL) undergoing autologous stem cell transplantation (ASCT)." | 1.56 | Therapeutic Dose Monitoring of Busulfan Is Associated with Reduced Risk of Relapse in Non-Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. ( Bolwell, B; Copelan, EA; Dean, RM; Gerds, AT; Hamilton, BK; Hill, BT; Jagadeesh, D; Kalaycio, ME; Lucena, M; Majhail, NS; Pohlman, B; Rybicki, LA; Sobecks, RM; Urban, TA, 2020) |
| "Lymphopenia was also a significant prognostic factor for progression-free survival (HR 3." | 1.43 | A new prognostic model using absolute lymphocyte count in patients with primary central nervous system lymphoma. ( Cheong, JW; Cho, H; Chung, H; Jang, JE; Kim, JS; Kim, SJ; Kim, Y; Kim, YR; Lee, JY; Min, YH; Park, H, 2016) |
| " To facilitate a therapeutic dose-monitoring protocol, we transitioned from Bu6 to daily Bu dosing for patients with Hodgkin and non-Hodgkin lymphoma undergoing autologous stem cell transplantation (ASCT)." | 1.43 | Daily Weight-Based Busulfan with Cyclophosphamide and Etoposide Produces Comparable Outcomes to Four-Times-Daily Busulfan Dosing for Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. ( Andresen, S; Bolwell, BJ; Carlstrom, KD; Dean, R; Gerds, A; Hamilton, B; Hill, BT; Jagadeesh, D; Kalaycio, M; Liu, H; Majhail, NS; Pohlman, B; Rybicki, L; Sobecks, R, 2016) |
| " Pharmacokinetic treatment with targeted intravenous busulfan combined with fludarabine (BuFlu) was developed as a preparative regimen for acute leukemia and myelodysplasia." | 1.42 | Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma. ( Anasetti, C; Ayala, E; Figueroa, J; Kharfan-Dabaja, MA; Kim, J; Locke, F; Nishihori, T; Perkins, J; Riches, M; Yue, B, 2015) |
| "IV busulfan was associated with a lower rate of relapse, and superior relapse-free survival (RFS) and OS." | 1.36 | Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide. ( Andresen, S; Bolwell, BJ; Copelan, EA; Curtis, J; Dean, RM; Kalaycio, ME; Pohlman, B; Rybicki, LA; Smith, SD; Sobecks, RM; Sweetenham, JW, 2010) |
| " After April 1999, 31 patients similar in all pretransplantation risk assessments received the same regimen except that intravenous (IV) Bu was substituted for PO Bu and pharmacokinetic-directed (PKD) dosing was attempted to achieve an area under the concentration time curve of 1000-1500 micromol/min for each dose." | 1.33 | Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen. ( Aggarwal, C; Carabasi, MH; Gupta, S; Katz, RO; Nance, AG; Salzman, DE; Saylors, GB; Tilden, AB; Vaughan, WP, 2006) |
| "This study reports on overall and recurrence-free survival (OS and RFS) of 37 consecutive patients with low- and intermediate-grade NHL receiving a related donor allogeneic BMT using a nonradiation-containing preparative regimen." | 1.32 | Busulfan and cyclophosphamide as a preparative regimen for allogeneic blood and marrow transplantation in patients with non-Hodgkin's lymphoma. ( Kiss, TL; Lipton, JH; Meharchand, J; Messner, HA; Panzarella, T; Reddy, V; Schimmer, AD, 2003) |
| " Routine dosing on the basis of BSA or AIBW in adults and adolescents does not require a specific accommodation for the obese." | 1.30 | The impact of obesity and disease on busulfan oral clearance in adults. ( Appelbaum, FR; Corneau, B; Gibbs, JP; Gooley, T; Murray, G; Slattery, JT; Stewart, P, 1999) |
| "Ten patients with non-Hodgkin's lymphoma (NHL) and nine with Hodgkin's Disease (HD) received high-dose busulfan and etoposide (VP-16) prior to autologous bone marrow transplantation (ABMT)." | 1.28 | Autologous bone marrow transplantation following high-dose busulfan and VP-16 for advanced non-Hodgkin's lymphoma and Hodgkin's disease. ( Bloom, EJ; Buck, DS; Przepiorka, D; Rosenfeld, CS; Schwinghammer, TL; Shadduck, RK, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 19 (20.43) | 18.7374 |
| 1990's | 20 (21.51) | 18.2507 |
| 2000's | 22 (23.66) | 29.6817 |
| 2010's | 21 (22.58) | 24.3611 |
| 2020's | 11 (11.83) | 2.80 |
| Authors | Studies |
|---|---|
| Sapelli, J | 1 |
| Filho, JS | 1 |
| Matias Vieira, GM | 1 |
| Moura, FL | 1 |
| Germano, JN | 1 |
| de Lima, VCC | 1 |
| Kim, KH | 1 |
| Lee, JH | 3 |
| Lee, M | 1 |
| Kim, HG | 1 |
| Do, YR | 1 |
| Park, Y | 1 |
| Oh, SY | 1 |
| Shin, HJ | 3 |
| Kim, WS | 3 |
| Park, SK | 1 |
| Kong, JH | 1 |
| Park, MR | 1 |
| Yang, DH | 2 |
| Kwak, JY | 1 |
| Kang, HJ | 1 |
| Mun, YC | 1 |
| Won, JH | 2 |
| Frietsch, JJ | 1 |
| Miethke, J | 1 |
| Linke, P | 1 |
| Crodel, CC | 1 |
| Schnetzke, U | 1 |
| Scholl, S | 1 |
| Hochhaus, A | 1 |
| Hilgendorf, I | 1 |
| Kaulen, LD | 1 |
| Baehring, JM | 1 |
| Kodama, Y | 1 |
| Saburi, M | 1 |
| Maruyama, R | 1 |
| Sakata, M | 1 |
| Takata, H | 1 |
| Miyazaki, Y | 1 |
| Kawano, K | 1 |
| Wada, J | 1 |
| Urabe, S | 1 |
| Hazuku, T | 1 |
| Ohtsuka, E | 1 |
| Kamijo, K | 1 |
| Shimomura, Y | 1 |
| Shinohara, A | 1 |
| Mizuno, S | 1 |
| Kanaya, M | 1 |
| Usui, Y | 1 |
| Kim, SW | 2 |
| Ara, T | 1 |
| Mizuno, I | 1 |
| Kuriyama, T | 1 |
| Nakazawa, H | 1 |
| Matsuoka, KI | 1 |
| Kusumoto, S | 1 |
| Maseki, N | 1 |
| Yamaguchi, M | 1 |
| Ashida, T | 1 |
| Onizuka, M | 1 |
| Fukuda, T | 1 |
| Atsuta, Y | 1 |
| Kondo, E | 1 |
| Hill, BT | 2 |
| Rybicki, LA | 2 |
| Urban, TA | 1 |
| Lucena, M | 1 |
| Jagadeesh, D | 2 |
| Gerds, AT | 1 |
| Dean, RM | 2 |
| Sobecks, RM | 2 |
| Pohlman, B | 4 |
| Bolwell, B | 1 |
| Kalaycio, ME | 2 |
| Hamilton, BK | 1 |
| Copelan, EA | 5 |
| Majhail, NS | 2 |
| Kim, DY | 1 |
| Chung, JS | 1 |
| Jo, JC | 2 |
| Cho, SH | 1 |
| Kim, JS | 2 |
| Lim, SN | 1 |
| Lee, SM | 1 |
| Yoon, SS | 1 |
| Kim, IH | 1 |
| Bae, SH | 2 |
| Lee, YJ | 1 |
| Choi, Y | 1 |
| Lee, WS | 1 |
| Ghosh, N | 1 |
| Ahmed, S | 1 |
| Ahn, KW | 1 |
| Khanal, M | 1 |
| Litovich, C | 1 |
| Aljurf, M | 2 |
| Bacher, VU | 1 |
| Bredeson, C | 1 |
| Epperla, N | 1 |
| Farhadfar, N | 1 |
| Freytes, CO | 2 |
| Ganguly, S | 1 |
| Haverkos, B | 1 |
| Inwards, D | 1 |
| Kamble, RT | 1 |
| Lazarus, HM | 2 |
| Lekakis, L | 1 |
| Murthy, HS | 1 |
| Nishihori, T | 2 |
| Ramakrishnan, P | 1 |
| Rizzieri, DA | 1 |
| Yared, JA | 1 |
| Kharfan-Dabaja, MA | 2 |
| Sureda, A | 1 |
| Hamadani, M | 1 |
| Ji, J | 1 |
| Liu, Z | 1 |
| Kuang, P | 1 |
| Dong, T | 1 |
| Chen, X | 1 |
| Li, J | 1 |
| Zhang, C | 1 |
| Liu, J | 1 |
| Zhang, L | 1 |
| Shen, K | 1 |
| Liu, T | 1 |
| Qualls, D | 1 |
| Sullivan, A | 1 |
| Li, S | 2 |
| Brunner, AM | 1 |
| Collier, K | 1 |
| Hochberg, E | 2 |
| Armand, P | 3 |
| Batchelor, TT | 2 |
| Chen, YB | 5 |
| DeFilipp, Z | 1 |
| Le Bourgeois, A | 1 |
| Labopin, M | 1 |
| Blaise, D | 2 |
| Ceballos, P | 1 |
| Vigouroux, S | 2 |
| Peffault de Latour, R | 1 |
| Marçais, A | 1 |
| Bulabois, CE | 1 |
| Bay, JO | 1 |
| Chantepie, S | 1 |
| Deconinck, E | 2 |
| Daguindau, E | 1 |
| Contentin, N | 1 |
| Yakoub-Agha, I | 1 |
| Cornillon, J | 1 |
| Mercier, M | 1 |
| Turlure, P | 1 |
| Charbonnier, A | 1 |
| Rorhlich, PS | 1 |
| N'Guyen, S | 1 |
| Maillard, N | 1 |
| Marchand, T | 1 |
| Mohty, M | 1 |
| Chevallier, P | 1 |
| Tavil, B | 1 |
| Erdem, AY | 1 |
| Azik, F | 1 |
| Isik, P | 1 |
| Metin, A | 1 |
| Emir, S | 1 |
| Uckan, D | 1 |
| Tunc, B | 1 |
| Koenigsmann, M | 1 |
| Casper, J | 3 |
| Kahl, C | 1 |
| Basara, N | 1 |
| Sayer, HG | 1 |
| Behre, G | 1 |
| Theurich, S | 1 |
| Christopeit, M | 1 |
| Mohren, M | 1 |
| Reichle, A | 1 |
| Metzner, B | 2 |
| Ganser, A | 1 |
| Stadler, M | 1 |
| Uharek, L | 1 |
| Balleisen, L | 1 |
| Hinke, A | 1 |
| Hinke, R | 1 |
| Niederwieser, D | 1 |
| Batchelor, T | 1 |
| Brezina, M | 1 |
| Jones, S | 1 |
| Del Rio, C | 1 |
| Curtis, M | 1 |
| Ballen, KK | 3 |
| Barnes, J | 1 |
| Chi, AS | 1 |
| Dietrich, J | 1 |
| Driscoll, J | 1 |
| Gertsner, ER | 1 |
| Hochberg, F | 1 |
| LaCasce, AS | 2 |
| McAfee, SL | 3 |
| Spitzer, TR | 3 |
| Nayak, L | 1 |
| Omuro, A | 1 |
| Correa, DD | 1 |
| DeAngelis, LM | 1 |
| Moskowitz, CH | 1 |
| Matasar, MJ | 1 |
| Kaley, TJ | 1 |
| Gavrilovic, IT | 1 |
| Nolan, C | 1 |
| Pentsova, E | 1 |
| Grommes, CC | 1 |
| Panageas, KS | 1 |
| Baser, RE | 1 |
| Faivre, G | 1 |
| Abrey, LE | 1 |
| Sauter, CS | 1 |
| Ayala, E | 1 |
| Figueroa, J | 1 |
| Perkins, J | 1 |
| Kim, J | 1 |
| Yue, B | 1 |
| Riches, M | 1 |
| Locke, F | 1 |
| Anasetti, C | 1 |
| Lane, AA | 1 |
| Logan, B | 1 |
| Zhu, X | 1 |
| Akpek, G | 1 |
| Artz, A | 1 |
| Bredeson, CN | 1 |
| Cooke, KR | 1 |
| Ho, VT | 1 |
| Olsson, R | 1 |
| Saber, W | 1 |
| McCarthy, P | 2 |
| Pasquini, MC | 2 |
| Sakellari, I | 1 |
| Mallouri, D | 1 |
| Batsis, I | 1 |
| Apostolou, C | 1 |
| Konstantinou, V | 1 |
| Abela, EM | 1 |
| Douka, V | 1 |
| Marvaki, A | 1 |
| Karypidis, K | 1 |
| Iskas, M | 1 |
| Baliakas, P | 1 |
| Kaloyannidis, P | 1 |
| Yannaki, E | 1 |
| Sotiropoulos, D | 1 |
| Kouvatseas, G | 1 |
| Smias, C | 1 |
| Anagnostopoulos, A | 1 |
| Jang, JE | 1 |
| Kim, YR | 1 |
| Kim, SJ | 3 |
| Cho, H | 1 |
| Chung, H | 1 |
| Lee, JY | 1 |
| Park, H | 1 |
| Kim, Y | 1 |
| Cheong, JW | 1 |
| Min, YH | 1 |
| Flowers, CR | 1 |
| Costa, LJ | 1 |
| Le-Rademacher, J | 1 |
| Lill, M | 1 |
| Shore, TB | 1 |
| Vaughan, W | 1 |
| Craig, M | 1 |
| Shea, TC | 1 |
| Horwitz, ME | 1 |
| Fay, JW | 1 |
| Mineishi, S | 1 |
| Rondelli, D | 2 |
| Mason, J | 1 |
| Braunschweig, I | 1 |
| Ai, W | 1 |
| Yeh, RF | 1 |
| Rodriguez, TE | 1 |
| Flinn, I | 1 |
| Comeau, T | 1 |
| Yeager, AM | 1 |
| Pulsipher, MA | 1 |
| Bence-Bruckler, I | 1 |
| Laneuville, P | 1 |
| Bierman, P | 1 |
| Chen, AI | 1 |
| Kato, K | 1 |
| Wang, Y | 1 |
| Xu, C | 1 |
| Smith, AJ | 1 |
| Waller, EK | 1 |
| Rybicki, L | 1 |
| Carlstrom, KD | 1 |
| Gerds, A | 1 |
| Hamilton, B | 1 |
| Liu, H | 1 |
| Dean, R | 1 |
| Sobecks, R | 1 |
| Andresen, S | 2 |
| Kalaycio, M | 2 |
| Bolwell, BJ | 3 |
| Yusuf, RZ | 1 |
| Dey, B | 1 |
| Yeap, BY | 1 |
| McAfee, S | 1 |
| Attar, E | 2 |
| Sepe, PS | 1 |
| Dube, C | 2 |
| Zaucha, R | 1 |
| Gooley, T | 3 |
| Holmberg, L | 2 |
| Gopal, AK | 1 |
| Press, O | 2 |
| Maloney, D | 1 |
| Bensinger, WI | 2 |
| Kerbauy, FR | 1 |
| Tirapelli, B | 1 |
| Akabane, H | 1 |
| Oliveira, JS | 1 |
| Escalón, MP | 1 |
| Stefanovic, A | 1 |
| Venkatraman, A | 1 |
| Pereira, D | 1 |
| Santos, ES | 1 |
| Goodman, M | 1 |
| Byrnes, JJ | 1 |
| Fernandez, HF | 1 |
| Lee, SC | 1 |
| Lee, DH | 2 |
| Suh, C | 3 |
| Sweetenham, JW | 1 |
| Smith, SD | 1 |
| Curtis, J | 1 |
| Ulrickson, M | 1 |
| Aldridge, J | 1 |
| Kim, HT | 1 |
| Hochberg, EP | 2 |
| Hammerman, P | 1 |
| Dey, BR | 1 |
| Grigg, AP | 2 |
| Stone, J | 1 |
| Milner, AD | 1 |
| Schwarer, AP | 1 |
| Wolf, M | 2 |
| Prince, HM | 1 |
| Seymour, J | 1 |
| Gill, D | 1 |
| Ellis, D | 1 |
| Bashford, J | 1 |
| Kebriaei, P | 1 |
| Madden, T | 1 |
| Kazerooni, R | 1 |
| Wang, X | 1 |
| Thall, PF | 1 |
| Ledesma, C | 1 |
| Nieto, Y | 1 |
| Shpall, EJ | 1 |
| Hosing, C | 1 |
| Qazilbash, M | 1 |
| Popat, U | 1 |
| Khouri, I | 2 |
| Champlin, RE | 1 |
| Jones, RB | 1 |
| Andersson, BS | 2 |
| Kim, JE | 1 |
| Yoo, C | 1 |
| Kim, S | 1 |
| Lee, JS | 1 |
| Park, CJ | 1 |
| Huh, J | 1 |
| Andion, M | 1 |
| Molina, B | 1 |
| Gonzalez-Vicent, M | 1 |
| Alonso, L | 1 |
| Hernandez, C | 1 |
| Lassaletta, A | 1 |
| Lopez-Ibor, B | 1 |
| Villa, M | 1 |
| Diaz, MA | 1 |
| Zain, J | 2 |
| Palmer, JM | 1 |
| Delioukina, M | 1 |
| Thomas, S | 1 |
| Tsai, NC | 1 |
| Nademanee, A | 2 |
| Popplewell, L | 2 |
| Gaal, K | 1 |
| Senitzer, D | 1 |
| Kogut, N | 2 |
| O'Donnell, M | 1 |
| Forman, SJ | 3 |
| Cote, GM | 1 |
| Muzikansky, A | 1 |
| Hochberg, FH | 1 |
| Drappatz, J | 1 |
| Fisher, DC | 1 |
| Abramson, JS | 1 |
| Campbell, P | 1 |
| Friebe, A | 1 |
| Foulstone, P | 1 |
| Grigg, A | 2 |
| Hempton, J | 1 |
| Bajel, A | 1 |
| Kiss, TL | 1 |
| Panzarella, T | 1 |
| Messner, HA | 1 |
| Meharchand, J | 1 |
| Reddy, V | 1 |
| Schimmer, AD | 1 |
| Lipton, JH | 2 |
| Knauf, W | 1 |
| Kiefer, T | 1 |
| Wolff, D | 1 |
| Steiner, B | 1 |
| Hammer, U | 1 |
| Wegener, R | 1 |
| Kleine, HD | 1 |
| Wilhelm, S | 1 |
| Knopp, A | 1 |
| Hartung, G | 1 |
| Dölken, G | 1 |
| Freund, M | 1 |
| PITNEY, WR | 1 |
| WEBER, RE | 1 |
| HELMAN, N | 1 |
| ROSSOLIMO, OK | 3 |
| LEPESHKINA, GN | 2 |
| PRESNOV, MA | 1 |
| CHORIN, VA | 1 |
| GOLDBERG, LE | 1 |
| STANISLAVSKAYA, MS | 1 |
| BLUMBERG, NA | 1 |
| VERTOGRADOVA, TP | 1 |
| ORIGENES, ML | 1 |
| BEATTY, EC | 1 |
| BRUBAKER, C | 1 |
| HAMMOND, D | 1 |
| HARTMANN, JR | 1 |
| SHORE, N | 1 |
| WILLIAMS, KO | 1 |
| HUTCHISON, JL | 1 |
| MORROW, LB | 1 |
| ANDERSON, RE | 1 |
| CLIFFORD, P | 1 |
| BHARDWAJ, BV | 1 |
| WHITTAKER, LR | 1 |
| Rao, PS | 1 |
| Reddy, P | 1 |
| Garban, F | 2 |
| Drillat, P | 1 |
| Makowski, C | 1 |
| Jacob, MC | 1 |
| Richard, MJ | 1 |
| Favrot, M | 1 |
| Sotto, JJ | 1 |
| Bensa, JC | 1 |
| Cahn, JY | 1 |
| Aggarwal, C | 1 |
| Gupta, S | 1 |
| Vaughan, WP | 1 |
| Saylors, GB | 1 |
| Salzman, DE | 1 |
| Katz, RO | 1 |
| Nance, AG | 1 |
| Tilden, AB | 1 |
| Carabasi, MH | 1 |
| Rodriguez, R | 1 |
| Ruel, N | 1 |
| Smith, E | 1 |
| Krishnan, A | 1 |
| Patane, K | 1 |
| Nakamura, R | 1 |
| Sarkodee-Adoo, C | 1 |
| Michallet, M | 1 |
| Porcher, R | 1 |
| Attal, M | 1 |
| Ades, L | 1 |
| Bernard, M | 1 |
| Tabrizi, R | 1 |
| Cassuto, JP | 1 |
| Chevalier, P | 1 |
| Facon, T | 1 |
| Ifrah, N | 1 |
| Renaud, M | 1 |
| Tilly, H | 1 |
| Vernant, JP | 1 |
| Kuentz, M | 1 |
| Bourhis, JH | 1 |
| Bordigoni, P | 1 |
| Lioure, B | 1 |
| Socié, G | 1 |
| Milpied, N | 1 |
| Kim, JG | 1 |
| Sohn, SK | 1 |
| Chae, YS | 1 |
| Lee, JJ | 1 |
| Kim, HJ | 1 |
| Jung, JS | 1 |
| Kim, DH | 1 |
| Eom, HS | 1 |
| Izaki, S | 1 |
| Goto, H | 1 |
| Okuda, K | 1 |
| Matsuda, M | 1 |
| Watanabe, Y | 1 |
| Fujioka, K | 1 |
| Hanzawa, N | 1 |
| Sumita, H | 1 |
| Takahashi, H | 1 |
| Goto, S | 1 |
| Kai, S | 1 |
| Sekiguchi, H | 1 |
| Funabiki, T | 1 |
| Sasaki, H | 1 |
| Ikuta, K | 1 |
| Yokota, S | 1 |
| Chunduri, S | 1 |
| Dobogai, LC | 1 |
| Peace, D | 1 |
| Saunthararajah, Y | 1 |
| Quigley, J | 1 |
| Chen, YH | 1 |
| Mahmud, N | 1 |
| Hurter, E | 1 |
| Beri, R | 1 |
| Rosenthal, MA | 1 |
| Sheridan, WP | 3 |
| Link, H | 1 |
| Arseniev, L | 1 |
| Bähre, O | 1 |
| Berenson, RJ | 1 |
| Battmer, K | 1 |
| Kadar, JG | 1 |
| Jacobs, R | 1 |
| Kühl, J | 1 |
| Schubert, J | 1 |
| Diedrich, H | 1 |
| Poliwoda, H | 1 |
| Scheid, C | 1 |
| Pettengell, R | 2 |
| Ghielmini, M | 1 |
| Radford, JA | 2 |
| Morgenstern, GR | 2 |
| Stern, PL | 1 |
| Crowther, D | 2 |
| van Besien, KW | 1 |
| Khouri, IF | 1 |
| Giralt, SA | 1 |
| Mehra, R | 2 |
| Przepiorka, D | 3 |
| Gajewski, JL | 1 |
| Bellare, N | 1 |
| Nath, R | 1 |
| Khalil, A | 1 |
| Ciobanu, N | 1 |
| Sparano, JA | 1 |
| Gucalp, R | 1 |
| Dutcher, JP | 1 |
| Wiernik, PH | 1 |
| Avalos, BR | 2 |
| Klein, JL | 1 |
| Kapoor, N | 2 |
| Tutschka, PJ | 2 |
| Klein, JP | 1 |
| Scarffe, JH | 1 |
| Harris, M | 1 |
| Woll, PJ | 1 |
| Deakin, DP | 1 |
| Ryder, D | 1 |
| Wilkinson, PM | 1 |
| de Magalhaes-Silverman, M | 1 |
| Lister, J | 1 |
| Rybka, W | 1 |
| Wilson, J | 1 |
| Ball, E | 1 |
| Al-Fiar, FZ | 1 |
| Colwill, R | 1 |
| Fyles, G | 1 |
| Spaner, D | 1 |
| Messner, H | 1 |
| van Besien, K | 1 |
| Thall, P | 1 |
| Korbling, M | 1 |
| Pugh, WC | 1 |
| Giralt, S | 1 |
| Anderlini, P | 1 |
| Amin, K | 1 |
| Mirza, N | 1 |
| Seong, D | 1 |
| Gajewski, J | 1 |
| Hester, J | 1 |
| Andersson, B | 1 |
| Cabanillas, F | 1 |
| Champlin, R | 1 |
| Schiffman, K | 1 |
| Buckner, CD | 2 |
| Maziarz, R | 1 |
| Maloney, DG | 1 |
| Appelbaum, FR | 2 |
| Lilleby, K | 1 |
| Clift, R | 1 |
| Zuckerman, N | 1 |
| Klarnet, J | 1 |
| Weaver, C | 1 |
| Chauncey, T | 1 |
| Weaver, CH | 1 |
| Schwartzberg, L | 1 |
| Rhinehart, S | 1 |
| West, J | 1 |
| Zhen, B | 1 |
| West, WH | 1 |
| Kröger, N | 2 |
| Hoffknecht, M | 1 |
| Hänel, M | 2 |
| Krüger, W | 2 |
| Zeller, W | 1 |
| Stockschläder, M | 1 |
| de Wit, M | 1 |
| Weh, HJ | 1 |
| Kabisch, H | 1 |
| Erttmann, R | 1 |
| Zander, AR | 2 |
| Gorczyńska, E | 1 |
| Toporski, J | 1 |
| Bogusławska-Jaworska, J | 1 |
| Słociak, M | 1 |
| Gibbs, JP | 2 |
| Corneau, B | 1 |
| Murray, G | 1 |
| Stewart, P | 1 |
| Slattery, JT | 2 |
| Ullery, LL | 1 |
| Ames, GW | 1 |
| Senecal, FM | 1 |
| Nagler, A | 1 |
| Slavin, S | 1 |
| Varadi, G | 1 |
| Naparstek, E | 1 |
| Samuel, S | 1 |
| Or, R | 1 |
| Penza, SL | 1 |
| Goormastic, M | 1 |
| Andresen, SW | 1 |
| Bechtel, TP | 1 |
| Scholl, MD | 1 |
| Elder, PJ | 1 |
| Ezzone, SA | 1 |
| O'Donnell, LC | 1 |
| Tighe, MB | 1 |
| Risley, GL | 1 |
| Young, DC | 1 |
| Soussain, C | 1 |
| Suzan, F | 1 |
| Hoang-Xuan, K | 1 |
| Cassoux, N | 1 |
| Levy, V | 1 |
| Azar, N | 1 |
| Belanger, C | 1 |
| Achour, E | 1 |
| Ribrag, V | 1 |
| Gerber, S | 1 |
| Delattre, JY | 1 |
| Leblond, V | 1 |
| Clarke, K | 1 |
| Szer, J | 1 |
| Sonnenberg, S | 1 |
| Bornhäuser, M | 1 |
| Kroschinsky, F | 1 |
| Hänel, A | 1 |
| Birkmann, J | 1 |
| Schmid, B | 1 |
| Hoffknecht, MM | 1 |
| Fiedler, F | 1 |
| Ehninger, G | 1 |
| Loiseau, HA | 1 |
| Hartmann, O | 1 |
| Valteau, D | 1 |
| McDowell, H | 1 |
| Brugières, L | 1 |
| Vassal, G | 1 |
| Kalifa, C | 1 |
| Patte, C | 1 |
| Lemerle, J | 1 |
| Emminger, W | 1 |
| Emminger-Schmidmeier, W | 1 |
| Peters, C | 1 |
| Gadner, H | 1 |
| Phillips, GL | 1 |
| Shepherd, JD | 1 |
| Barnett, MJ | 1 |
| Lansdorp, PM | 1 |
| Klingemann, HG | 1 |
| Spinelli, JJ | 1 |
| Nevill, TJ | 1 |
| Chan, KW | 1 |
| Reece, DE | 1 |
| Rosenfeld, CS | 1 |
| Schwinghammer, TL | 1 |
| Buck, DS | 1 |
| Bloom, EJ | 1 |
| Shadduck, RK | 1 |
| Gibbins, B | 1 |
| Morstyn, G | 1 |
| Dodds, A | 1 |
| Lusk, J | 1 |
| Maher, D | 1 |
| Layton, JE | 1 |
| Green, MD | 2 |
| Souza, L | 1 |
| Fox, RM | 1 |
| Boyd, AW | 1 |
| Russell, DM | 1 |
| Thomas, RJ | 1 |
| McGrath, KM | 1 |
| Vaughan, SL | 1 |
| Scarlett, JD | 1 |
| Griffiths, JD | 1 |
| Brodie, GN | 1 |
| Blume, KG | 1 |
| Armstrong, JG | 1 |
| Van Hove, WZ | 1 |
| Cohen, ML | 1 |
| Weiss, EB | 1 |
| Hartwich, G | 1 |
| Butzler, W | 1 |
| Galton, DA | 1 |
| White, LP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Chidamide Combined With Cladribine/Gemcitabine/Busulfan (ChiCGB) With Autologous Stem-Cell Transplantation in Relapsed and Refractory Diffuse Large B Cell Lymphoma[NCT03151876] | Phase 2 | 93 participants (Anticipated) | Interventional | 2017-06-12 | Recruiting | ||
| Phase II Trial of Hihg-Dose Thiotepa, Busulfan, Cyclophosphamide, and Rituximab With Autologous Stem Cell Transplantation for Patients With CNS Involvement by Non-Hodgkin's Lymphoma or Primary CNS Lymphoma[NCT01182415] | Phase 2 | 30 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| A Phase II， Single-arm Trail of Chidamide Combined With Rituximab and High-dose Methotrexate in Previously Untreated Patients With Primary Central Nervous System Lymphoma[NCT04516655] | Phase 2 | 51 participants (Anticipated) | Interventional | 2020-09-01 | Not yet recruiting | ||
| Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma (PCNSL)[NCT00596154] | Phase 2 | 33 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| A Phase II, Multicenter, Prospective, Non-randomised, Open-label, Clinical Trial to Evaluate Effectiveness and Safety of BeEAC Conditioning Regimen in Malignant Lymphoma Subjects With Indications to Autologous Hematopoietic Stem-cell Transplantation[NCT03315520] | Phase 2 | 100 participants (Anticipated) | Interventional | 2016-01-22 | Recruiting | ||
| Safety and Efficacy of Ibritumomab Tiuxetan (Zevalin®) in Association With a Fludarabine Based Reduced Conditioning Regimen and Allogenic Stem Cell Support in Chemo-sensitive Relapsed CD20 Positive Aggressive Non-Hodgkin's Lymphoma Patients.[NCT00607854] | Phase 2 | 31 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Safety and Efficacy of a Strategy of Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Chemosensitive Relapsed Follicular Lymphoma[NCT01208896] | Phase 2 | 32 participants (Actual) | Interventional | 2011-02-03 | Completed | ||
| A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793] | Phase 2 | 11 participants (Actual) | Interventional | 2010-10-14 | Terminated (stopped due to The clinical trial was terminated due to poor enrollment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The percentage of participants alive after two years (NCT01182415)
Timeframe: 2 years
| Intervention | percentage of participants (Number) |
|---|---|
| High-dose Chemotherapy With Autologous Stem Cell Transplant | 93 |
The percentage of participants alive and without disease progression at 2 years. Disease progression was judged through clinical impression and MRI imaging. (NCT01182415)
Timeframe: 2 years
| Intervention | percentage of participants (Number) |
|---|---|
| High-dose Chemotherapy With Autologous Stem Cell Transplant | 81 |
The proportion of patients with central nervous system (CNS) involvement by B-cell Non-Hodgkin's Lymphoma (NHL), relapsed primary central nervous system lymphoma (PCNSL), or relapsed primary intraocular lymphoma (PIOL) who are alive and progression-free at one year. Relapse was defined as per standard PCNSL criteria from clinical and MRI criteria. (NCT01182415)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| High-dose Chemotherapy With Autologous Stem Cell Transplant | 28 |
The number of participants that achieved complete remission following high dose chemotherapy and autologous stem cell transplantation (ASCT). Complete remission is defined as the disappearance of all evidence of disease. Response was judged by MRI assessment. (NCT01182415)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| High-dose Chemotherapy With Autologous Stem Cell Transplant | 29 |
Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year
| Intervention | dose in mg/m^2 (Number) |
|---|---|
| DRBEAT Regimen | 773.25 |
"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years
| Intervention | Days (Median) | |
|---|---|---|
| Progression Free Survival | Overall Survival | |
| DRBEAT Regimen | 132 | 564 |
3 reviews available for busulfan and Diffuse Mixed Small and Large Cell Lymphoma
| Article | Year |
|---|---|
Treatment Options for Recurrent Primary CNS Lymphoma.
Topics: Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms | 2022 |
High-dose chemotherapy with busulphan and cyclophosphamide and bone-marrow transplantation for drug-sensitive malignancies in adults: a preliminary report.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamid | 1989 |
[Lactate dehydrogenase in human leukemia. A clinico-experimental study].
Topics: Adult; Aged; Animals; Antibiotics, Antineoplastic; Bone Marrow; Bone Marrow Cells; Busulfan; Endotox | 1972 |
25 trials available for busulfan and Diffuse Mixed Small and Large Cell Lymphoma
| Article | Year |
|---|---|
Busulfan, Melphalan, and Etoposide (BuME) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High-Risk Non-Hodgkin's Lymphoma: A Mul
Topics: Antineoplastic Combined Chemotherapy Protocols; Behavior Therapy; Busulfan; Cyclophosphamide; Etopos | 2023 |
Phase II study of safety and efficacy of BEB (bendamustine, etoposide, and busulfan) conditioning regimen for autologous stem cell transplantation in non-Hodgkin lymphoma.
Topics: Adult; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride | 2020 |
A new conditioning regimen with chidamide, cladribine, gemcitabine and busulfan significantly improve the outcome of high-risk or relapsed/refractory non-Hodgkin's lymphomas.
Topics: Adolescent; Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; | 2021 |
Risk-adapted, treosulfan-based therapy with auto- and allo-SCT for relapsed/refractory aggressive NHL: a prospective phase-II trial.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2014 |
Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2015 |
R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2015 |
R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2015 |
R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2015 |
Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.
Topics: Adult; Aged; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Drug Combinations; Etoposide; Hemat | 2016 |
The effect of administration order of BU and CY on toxicity in hematopoietic SCT in humans.
Topics: Adolescent; Adult; Anemia, Aplastic; Busulfan; Cohort Studies; Cyclophosphamide; Follow-Up Studies; | 2009 |
Phase II study of autologous stem cell transplant using busulfan-melphalan chemotherapy-only conditioning followed by interferon for relapsed poor prognosis follicular non-Hodgkin lymphoma.
Topics: Adult; Busulfan; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Huma | 2010 |
Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busu | 2011 |
BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cyclo | 2011 |
Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation.
Topics: Acute Disease; Adult; Aged; Alkylating Agents; Busulfan; Chronic Disease; Family; Female; Histocompa | 2004 |
Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both?
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Disease-Free Survival; Drug Therapy, Combi | 2008 |
High dose busulphan/cyclophosphamide for autologous bone marrow transplantation is associated with minimal non-hemopoietic toxicity.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protoco | 1994 |
Combined transplantation of allogeneic bone marrow and CD34+ blood cells.
Topics: Adult; Antigens, CD; Antigens, CD34; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cyclos | 1995 |
Pilot study of high-dose mitoxantrone and busulfan plus autologous bone transplantation in patients with advanced malignancies.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Bone Marrow Trans | 1995 |
Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Busulfan; Combined Mod | 1996 |
Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients.
Topics: Adult; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Disease-Free Survival; Drug Therapy, | 1997 |
High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Combined Modality Thera | 1998 |
Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Cyclophosphamid | 2000 |
Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; C | 2001 |
Prolonged disease-free survival after autografting for chemosensitive non-bulky low grade non-Hodgkin's Lymphoma.
Topics: Actuarial Analysis; Adult; Busulfan; Combined Modality Therapy; Disease-Free Survival; Female; Follo | 2000 |
Busulfan, cyclophosphamide, and melphalan conditioning for autologous bone marrow transplantation in hematologic malignancy.
Topics: Actuarial Analysis; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantati | 1991 |
Allogeneic marrow transplantation in non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busu | 1990 |
Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation.
Topics: Agranulocytosis; Bone Marrow Examination; Bone Marrow Transplantation; Busulfan; Clinical Trials as | 1989 |
65 other studies available for busulfan and Diffuse Mixed Small and Large Cell Lymphoma
| Article | Year |
|---|---|
BuCyE can safely replace BEAM as a conditioning regimen for autologous stem cell transplantation in the treatment of refractory and relapsed lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Combi | 2021 |
Treosulfan plus fludarabine versus TEAM as conditioning treatment before autologous stem cell transplantation for B-cell Non-Hodgkin lymphoma.
Topics: Aged; Busulfan; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Retrospectiv | 2022 |
[Busulfan/thiotepa followed by autologous peripheral blood stem cell transplantation for refractory diffuse large B-cell lymphoma accompanied by hypopyon].
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Doxorubicin; Humans; Lym | 2022 |
Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation.
Topics: Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, N | 2023 |
Therapeutic Dose Monitoring of Busulfan Is Associated with Reduced Risk of Relapse in Non-Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Hematopoietic Ste | 2020 |
Busulfan, etoposide, cytarabine, and melphalan (BuEAM) as a conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma (NHL).
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cytarabine; Etoposide; Hematopoietic Stem | 2020 |
Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant.
Topics: Allografts; Busulfan; Cohort Studies; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Hum | 2020 |
High-dose Thiotepa, Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplantation as Upfront Consolidation for Systemic Non-Hodgkin Lymphoma With Synchronous Central Nervous System Involvement.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System; Combi | 2017 |
Reduced-intensity versus reduced-toxicity myeloablative fludarabine/busulfan-based conditioning regimens for allografted non-Hodgkin lymphoma adult patients: a retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cel
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Graft vs Host Disease | 2017 |
Successful allogeneic hemopoietic stem cell transplantation in a case of Wiskott-Aldrich syndrome and non-Hodgkin lymphoma.
Topics: Antilymphocyte Serum; Blood Platelets; Busulfan; Child; Hematopoietic Stem Cell Transplantation; His | 2013 |
Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma.
Topics: Administration, Intravenous; Adult; Aged; Antineoplastic Agents; Busulfan; Disease-Free Survival; Dr | 2015 |
Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Drug | 2015 |
Carmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced Hodgk
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cytarabine; Female; Fol | 2015 |
A new prognostic model using absolute lymphocyte count in patients with primary central nervous system lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neopla | 2016 |
Daily Weight-Based Busulfan with Cyclophosphamide and Etoposide Produces Comparable Outcomes to Four-Times-Daily Busulfan Dosing for Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
Topics: Adult; Aged; Busulfan; Cyclophosphamide; Drug Administration Schedule; Etoposide; Female; Hematopoie | 2016 |
Autologous SCT with a dose-reduced BU and CY regimen in older patients with non-Hodgkin's lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Cyclophos | 2009 |
High-dose chemotherapy with BEAM or Busulphan/Melphalan and Thiotepa followed by hematopoietic cell transplantation in malignant lymphoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busu | 2008 |
Autologous transplantation for relapsed non-Hodgkin's lymphoma using intravenous busulfan and cyclophosphamide as conditioning regimen: a single center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Disease Pro | 2009 |
Excessive toxicity of once daily i.v. BU, melphalan and thiotepa followed by auto SCT on patients with non-Hodgkin's lymphoma.
Topics: Adult; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Hu | 2010 |
Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Age | 2010 |
Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Busulfan; Combined | 2009 |
High-dose busulfan and cyclophosphamide as a conditioning regimen for autologous peripheral blood stem cell transplantation in childhood non-Hodgkin lymphoma patients: a long-term follow-up study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cyclo | 2011 |
Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Cyclophosp | 2011 |
Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neopla | 2012 |
Impact of palifermin on mucosal toxicity in autologous stem cell transplants using busulfan-melphalan conditioning chemotherapy for Hodgkin and non-Hodgkin lymphoma.
Topics: Adult; Busulfan; Drug Administration Schedule; Female; Fibroblast Growth Factor 7; Gastric Mucosa; H | 2012 |
Busulfan and cyclophosphamide as a preparative regimen for allogeneic blood and marrow transplantation in patients with non-Hodgkin's lymphoma.
Topics: Adult; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Disease-Free Survival; Female; Follo | 2003 |
Chemotherapy of malignant disease. II. Diseases of lymphoid tissue and bone marrow.
Topics: Adrenal Cortex Hormones; Aged; Bone Marrow; Busulfan; Chlorambucil; Cyclophosphamide; Hodgkin Diseas | 1962 |
THE LOCAL INFLAMMATORY RESPONSE IN PATIENTS WITH BLOOD DYSCRASIAS AS TESTED BY THE SKIN WINDOW TECHNIQUE.
Topics: Busulfan; Hodgkin Disease; Inflammation; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukocyte | 1963 |
[EXPERIMENTAL STUDIES ON THE ANTITUMOR EFFECT OF OLIVOMYCIN IN ASSOCIATION WITH SOME SYNTHETIC CYTOSTATIC PREPARATIONS].
Topics: Animals; Anti-Bacterial Agents; Antibiotics, Antitubercular; Antineoplastic Agents; Busulfan; Cytost | 1963 |
HISTOLOGICAL AND HISTOCHEMICAL DATA ON THE PROCESS OF REGRESSION OF EXPERIMENTAL TUMOURS INDUCED BY ALKYLATING AGENTS.
Topics: Alkaline Phosphatase; Alkylating Agents; Animals; Antineoplastic Agents; Aziridines; Busulfan; Carci | 1964 |
EXPERIMENTAL STUDY OF OLIVOMYCIN, AN ANTITUMOUR ANTIBIOTIC.
Topics: Animals; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antineoplastic Agents; Busulfan; Carcin | 1964 |
TRIAL OF HYDROXYUREA (NSC-32065) IN CANCER IN CHILDREN.
Topics: Antineoplastic Agents; Busulfan; Child; Cyclophosphamide; Dactinomycin; Humans; Hydroxyurea; Leukemi | 1964 |
THE MANAGEMENT OF LEUKEMIA AND LYMPHOMA.
Topics: Adrenal Cortex Hormones; Busulfan; Chlorambucil; Cortisone; Cyclophosphamide; Hodgkin Disease; Human | 1964 |
ACTIVE TUBERCULOSIS IN LEUKEMIA. MALIGNANT LYMPHOMA AND MYELOFIBROSIS.
Topics: Alkylating Agents; Aminopterin; Busulfan; Hodgkin Disease; Humans; Leukemia; Leukemia, Lymphoid; Leu | 1965 |
INTENSIVE NITROGEN MUSTARD THERAPY WITH ABDOMINAL AORTIC OCCLUSION IN NASOPHARYNGEAL CARCINOMA.
Topics: Adenocarcinoma; Antineoplastic Agents; Aorta; Aorta, Abdominal; Busulfan; Carcinoma; Carcinoma, Squa | 1965 |
Nephrotic syndrome in patients with peripheral blood stem cell transplant.
Topics: Acute Kidney Injury; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineop | 2005 |
Extracorporeal photo-chemotherapy for graft-versus-host disease.
Topics: Busulfan; Graft vs Host Disease; Hematologic Neoplasms; Humans; Leukemia; Lymphoma, Non-Hodgkin; Pho | 2005 |
Extracorporeal chemophototherapy for the treatment of graft-versus-host disease: hematologic consequences of short-term, intensive courses.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Busulfan; Female; Graft vs Host Disease; Hematologic | 2005 |
Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen.
Topics: Administration, Oral; Adolescent; Adult; Aged; Busulfan; Chi-Square Distribution; Cyclophosphamide; | 2006 |
Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Busulfan; Cause of Death; Cohort Studies; Cyclophosphamide; Disease-Free Su | 2006 |
Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).
Topics: Adult; Aged; Antibodies, Monoclonal; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Prot | 2007 |
Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu/Cy/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Etopo | 2007 |
Long-term follow-up of busulfan, etoposide, and nimustine hydrochloride (ACNU) or melphalan as conditioning regimens for childhood acute leukemia and lymphoma.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; C | 2007 |
Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Diseases; | 1995 |
Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cispla | 1995 |
Preparation for marrow transplantation in Hodgkin's and non-Hodgkin's lymphoma using Bu/CY.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Thera | 1993 |
Busulfan and cyclophosphamide (BU/CY2) as preparative regimen for patients with lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; | 1997 |
Abnormal thyroid stimulating hormone (TSH) levels in adults following allogeneic bone marrow transplants.
Topics: Adolescent; Adult; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Dise | 1997 |
High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality | 1997 |
Busulfan, cyclophosphamide and etoposide as high-dose conditioning therapy in patients with malignant lymphoma and prior dose-limiting radiation therapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busu | 1998 |
High-dose chemotherapy with autologous hematopoietic progenitor cell transplantation in children with high-risk NHL and ALL-preliminary results.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cyclo | 1998 |
The impact of obesity and disease on busulfan oral clearance in adults.
Topics: Administration, Oral; Adolescent; Adult; Body Mass Index; Body Surface Area; Body Weight; Busulfan; | 1999 |
Busulfan clearance in renal failure and hemodialysis.
Topics: Administration, Oral; Biological Availability; Blood Transfusion, Autologous; Busulfan; Hematopoieti | 2000 |
Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
Topics: Adolescent; Adult; Antilymphocyte Serum; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 2000 |
Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Thera | 2002 |
High-dose chemotherapy containing busulfan followed by bone marrow transplantation in 24 children with refractory or relapsed non-Hodgkin's lymphoma.
Topics: Adolescent; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Dose-Res | 1991 |
Influence of immunosuppression on acute liver toxicity after intensified conditioning regimens for bone marrow transplantation in children.
Topics: Bone Marrow Transplantation; Busulfan; Child; Cyclosporins; Drug Therapy, Combination; Etoposide; Gr | 1991 |
Autologous bone marrow transplantation following high-dose busulfan and VP-16 for advanced non-Hodgkin's lymphoma and Hodgkin's disease.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow | 1991 |
High dose busulfan/etoposide as a preparatory regimen for second bone marrow transplants in hematologic malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Bone Marrow Tr | 1987 |
Current problems in the use of the oncolytic drugs.
Topics: Antineoplastic Agents; Busulfan; Carcinoma, Squamous Cell; Child; Chlorambucil; Choriocarcinoma; Dac | 1968 |
Pneumocystitis carinii pneumonia: percutaneous lung biopsy and review of literature.
Topics: Adolescent; Adult; Agammaglobulinemia; Amphotericin B; Anuria; Azathioprine; Biopsy; Bis-Trimethylam | 1971 |
[Experimental study of antitumor action of rubomycin in combination with some cytostatic compounds].
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Busulfan; Drug Synergism; Lymphoma, Non | 1967 |
[Secondary tumors in hemoblastoses during cytostatic treatment].
Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Agents; Bronchial Neoplasms; Busulfan; Carcinoma; Chlo | 1971 |
Some problems in the management of leukaemia and lymphoma.
Topics: Antineoplastic Agents; Busulfan; Cyclophosphamide; Female; Humans; Leukemia; Leukemia, Lymphoid; Leu | 1966 |
Leukemia and lymphoma.
Topics: Antineoplastic Agents; BCG Vaccine; Burkitt Lymphoma; Busulfan; Chlorambucil; Cyclophosphamide; Cyta | 1970 |